Literature DB >> 2475568

Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes.

J L Whitton1, M B Oldstone.   

Abstract

Since class I MHC glycoproteins may function by "screening and selecting" degraded proteins, we wished to determine whether very short peptides made within a cell were detected and bound by MHC, and presented for T cell perusal. We show that a 22 amino acid viral sequence containing a Db-restricted nonameric CTL epitope is sufficient to direct CTL recognition/lysis of H2b target cells. The mechanism of epitope presentation is by the "natural" endogenous route, and appears to direct lysis as effectively as wild-type virus infection, in which the epitope is part of a 236 residue glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475568      PMCID: PMC2189441          DOI: 10.1084/jem.170.3.1033

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Cytotoxic T cells recognize fragments of the influenza nucleoprotein.

Authors:  A R Townsend; F M Gotch; J Davey
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

Review 2.  MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

3.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

4.  Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus.

Authors:  J L Whitton; J R Gebhard; H Lewicki; A Tishon; M B Oldstone
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

5.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. V. Recognition is restricted to gene products encoded by the viral S RNA segment.

Authors:  Y Riviere; P J Southern; R Ahmed; M B Oldstone
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

6.  Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus.

Authors:  P J Southern; M K Singh; Y Riviere; D R Jacoby; M J Buchmeier; M B Oldstone
Journal:  Virology       Date:  1987-03       Impact factor: 3.616

Review 7.  The virology and immunobiology of lymphocytic choriomeningitis virus infection.

Authors:  M J Buchmeier; R M Welsh; F J Dutko; M B Oldstone
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

8.  Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus.

Authors:  J L Whitton; P J Southern; M B Oldstone
Journal:  Virology       Date:  1988-02       Impact factor: 3.616

9.  Fine dissection of a nine amino acid glycoprotein epitope, a major determinant recognized by lymphocytic choriomeningitis virus-specific class I-restricted H-2Db cytotoxic T lymphocytes.

Authors:  M B Oldstone; J L Whitton; H Lewicki; A Tishon
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

10.  The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells.

Authors:  A R Townsend; J J Skehel
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  24 in total

1.  Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope.

Authors:  M Del Val; H J Schlicht; H Volkmer; M Messerle; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

Review 2.  Molecular anatomy of viral persistence.

Authors:  M B Oldstone
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Do we need a pepton hypothesis?

Authors:  K F Lindahl
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

4.  A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge.

Authors:  J L Whitton; N Sheng; M B Oldstone; T A McKee
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

5.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen.

Authors:  L L An; J L Whitton
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes.

Authors:  T M Fu; R H Bonneau; M J Tevethia; S S Tevethia
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination.

Authors:  M B Oldstone; A Tishon; R Geckeler; H Lewicki; J L Whitton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

9.  Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein.

Authors:  F Buseyne; M McChesney; F Porrot; S Kovarik; B Guy; Y Rivière
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus.

Authors:  M Manchester; M K Liszewski; J P Atkinson; M B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.